Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03585764 · ClinicalTrials.gov registry record · Phase 1
MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase 1 study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT03585764: Clinical Trial Phase 1 study, sponsored by University of Pennsylvania.
NCT03585764 is a Phase 1 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 46 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03585764, a Phase 1 study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
Phase I study to establish safety and feasibility of intraperitoneally administered lentiviral transduced MOv19-BBz CAR T cells with or without cyclophosphamide + fludarabine as lymphodepleting chemotherapy
Interventions
- DRUG MOv19-BBz CAR T cells
- DEVICE Alpha Folate Receptor expression test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2018-10-24 |
| Est. Completion | 2024-03-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03585764
The ClinicalTrials.gov registry entry for NCT03585764 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MOv19-BBz CAR T cells is the first listed.
NCT03585764 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03585764 about?
NCT03585764 is a clinical study titled "MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer". Phase I study to establish safety and feasibility of intraperitoneally administered lentiviral transduced MOv19-BBz CAR T cells with or without cyclophosphamide + fludarabine as lymphodepleting chemotherapy
What is the current status of trial NCT03585764?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2018-10-24. Estimated completion is 2024-03-26.
What interventions are being tested in trial NCT03585764?
The interventions under investigation include: MOv19-BBz CAR T cells (DRUG), Alpha Folate Receptor expression test (DEVICE).
Who is sponsoring clinical trial NCT03585764?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.